Objectives: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection-related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. Methods: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. Results: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. Significance: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.
applied late in the disease course when changes in disease markers might be altered by polypharmacy, seizure burden, and complications of critical illness.
The hypothesis regarding FIRES etiology is based on evidence of inflammatory interplay and epileptogenesis extrapolated from status epilepticus (SE) research to FIRES. In genetically predisposed individuals, a nonspecific febrile illness triggers the release of inflammatory molecules via innate immune activation and through various mechanisms promotes hyperexcitability. 2, 5 Another hyperinflammatory disorder is hemophagocytic lymphohistiocytosis (HLH), which is characterized by uncontrolled activation of histiocyte and lymphocytes resulting in hypercytokinemia and hemophagocytosis. 6, 7 HLH is classified as primary due to genetic mutations and secondary due to malignancy, autoinflammatory, infectious, or metabolic conditions. 6 In secondary HLH, the role of innate immune activation via stimulation of Toll-like receptors has been highlighted. 8 Five of 8 criteria are necessary to diagnose secondary HLH ( Figure 1 ). 9 Secondary HLH is usually underrecognized due to lack of criteria specificity, 10 which is why some experts recommend HLH screening in febrile, critically ill patients with multiorgan dysfunction, ≥2 cytopenias, or splenomegaly.
11
Although secondary HLH has been reported with infections, malignancies, and autoimmune disorders, 12 it has never been reported in patients with FIRES. We describe our experience with HLH in patients with FIRES and explore a potential pathophysiologic mechanism of secondary systemic and neurologic inflammation.
| METHODS
We performed a retrospective analysis of 10 patients with FIRES from 2007 to 2017. Patients were identified from a prospective neurocritical care database. The electronic medical record was used to supplement patient demographics and clinical course information. All had (1) super-refractory status epilepticus (defined as status epilepticus that continues or recurs 24 hours or more after the onset of anesthesia 13 ) preceded by a nonspecific febrile illness; (2) an extensive evaluation for infectious, structural, metabolic, and immunologic triggers that did not reveal an etiology for the refractory seizures; and (c) no evidence of chronic disease. Patients were excluded if they had preexistent epilepsy, were younger than 2 years, had a known neurologic disease, or had another diagnosis to explain the clinical presentation. Five children were assessed for HLH. Our institution routinely screens most severely critically ill children with ferritin levels if they have unexplained multiorgan dysfunction, fever, or cytopenias. The sixth patient with FIRES cared for at our institution (Patient 1) had associated multiorgan dysfunction, fever, and cytopenias prompting clinicians to assess her for HLH. All subsequent patients with FIRES (n = 5) have been fully or partially screened for HLH and thus are included in this study.
All 5 patients screened for HLH had further assessment of their inflammatory state. Cerebrospinal fluid (CSF) frozen at −80°C was assessed for cytokine and chemokine levels a minimum of once in the disease course. Matched serum cytokines and chemokines were measured in 2 patients at least once in the disease course. Cytokine and chemokine analysis was performed at the translational neuroimmunology laboratory at Mayo Clinic. This study was approved by the institutional review boards at both Children's National Health System and Mayo Clinic.
| FIRES diagnosis-clinical/laboratory features
For a comprehensive list of specific tests performed in each patient, please refer to Table S1 . 
| Outcomes
Outcomes were assessed 6 months after presentation. Outcome analysis included the presence of refractory epilepsy, cognitive state, functional assessment, dependence on medical devices (ie, gastrostomy or tracheostomy with our without ventilator support), and mortality.
| Cytokine and chemokine analysis
CSF was collected from all 5 patients; matched serum was available from 2. CSF controls utilized derive from adult patients with normal pressure hydrocephalus. Serum controls were obtained from healthy adults. Interleukin (IL)-1β, IL-6, IL-10, IL-12p70, and tumor necrosis factor (TNF)-α were measured using an inflammatory cytokine-specific cytometric bead array (#551811, BD Biosciences, San Diego, California). C-C motif chemokine ligand (CCL)-2, CCL5, C-X-C motif chemokine ligand (CXCL)8, CXCL9, and CXCL10 were also measured by cytometric bead array (#552990, BD Biosciences) using an Accuri C6 flow cytometer (BD Biosciences). Limits of detection for the inflammatory cytokine kit were as follows: 7.2 pg/mL IL-1β; 2.5 pg/mL IL-6; 3.3 pg/mL IL-10; 3.7 pg/mL TNF-α; and 1.9 pg/mL IL-12p70. Limits of detection for the chemokine kit were as follows: 2.7 pg/mL CCL2; 1.0 pg/mL CCL5; 0.2 pg/mL CXCL8; 2.5 pg/mL CXCL9; and 2.8 pg/ mL CXCL10. Quantitation was performed by reference to a standard curve using FCAP Array software (BD Biosciences) and manual analysis in FlowJo 10.1 (Ashland, Oregon). Results are expressed as pg/mL for each analyte. 
| Statistics
Wilcoxon rank-sum test was used to compare median CSF neopterin for patients with FIRES to published median CSF neopterin values in the following conditions 14 : acute disorders (n = 30), chronic progressive disorders (n = 17), febrile exacerbation of chronic static disorders (n = 6), and chronic static disorders (n = 105). The P values were adjusted for the number of comparisons using the Sidak method. Data analysis was performed using Stata 14 (College Station, Texas).
| RESULTS
Patient characteristics are summarized in Three patients fulfilled ≥5 diagnostic criteria for secondary HLH. The other 2 patients met 3 and 4 criteria but were incompletely screened. Three patients were genetically screened for HLH, and none had a known genetic mutation. Four patients exhibited a maculopapular rash within 2 days of HLH surveillance. Additional clinical features identified during HLH screening included elevation of transaminases in all patients with cholestasis in 3, renal dysfunction in one patient, hemodynamic instability and 
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ileus in 3 patients, and disseminated intravascular coagulation in 2 patients. CSF neopterin was sent in all patients as part of the diagnostic work-up for CNS inflammation (reference range 7-40 nmol/L). In our patients with FIRES, the levels ranged from 122 to 300 nmol/L (median 260, IQR 188-297). Median CSF neopterin was higher in comparison with previously published neopterin levels in acute disorders (P = 0.0187), chronic progressive disorders (P = 0.0036), and static disorders (P = 0.0008). There was no significant difference between the median CSF neopterin value of FIRES patients and reported median value for "febrile exacerbation of chronic illnesses." 14 Individual cytokine and chemokine measurements are described in detail in Table 2 . Figure 2 demonstrates the temporal characteristics of the disease course and treatments employed in each of the 5 patients in this study. Cytokine and chemokine data during the HLH screening phase are demonstrated for 4 patients in Figure 3 (Patient 4 lacked analysis during this phase). Notably, the levels of IL-1β and IL-18 were not elevated in any of the subjects during any of the CSF sampling times and indeed failed to reach detection threshold in many of the patients ( Figure 2 ; Table 2 ). However, HMGB1 and CXCL8 were substantially elevated in CSF in all patients during the HLH screening phase ( Figure 3 ; Table 2 ). IL-6 was markedly increased in CSF in 2 patients; CXCL9 was elevated in one subject; CXCL10 was strongly elevated in one patient and more weakly elevated in another 3; and CCL5 was detectably increased in 2 patients during the HLH screening phase ( Figure 3 ; Table 2 ). Table 2 also indicates that many of these factors were elevated outside of the HLH screening phase. For example, Patient 4, who did not have a sample during the HLH screening phase, exhibited elevated CSF levels of HMGB1, CXCL8, CXCL9, and CXCL10, as well as exceptionally high levels of CCL5, at a point greater than 90 days from presentation. For the subjects with matched serum and CSF samples, we detected high levels of IL-1RA at several sampling points, consistent with anakinra treatment (Figure 2 ; Table 2 ). These patients also exhibited high levels of CRP and IL-6 in serum at several time points (Table 2) . Table 1 summarizes the time course of treatments administered, excluding antiseizure drugs and anesthetics. All patients received immunoglobulin and methylprednisolone early in their disease course for presumed immune-mediated encephalitis. Plasmapheresis was administered in 4. Ketogenic diet (KD) was initiated in all patients at different times during the course of disease and maintained for a variable amount of time. Four patients received rituximab and one received cyclophosphamide. Four patients received anakinra. Outcomes 6 months after FIRES diagnosis were variable. All patients had medically refractory epilepsy. Of the 3 patients diagnosed with HLH, only one patient (Patient 1) was treated with chemotherapy for secondary HLH with central nervous system (CNS) involvement per the 2004 Histiocyte Society recommendations. 9 Within days of treatment initiation, the seizures subsided and encephalopathy markedly improved. At 6-month follow-up, she had mild cognitive impairment but was independent for all activities of daily living (ADLs). One patient (Patient 5) was partially treated for HLH with highdose dexamethasone. At 6 months, she had severe cognitive impairment necessitating a gastrostomy and tracheostomy with ventilator support and was dependent for ADLs. Patient 2 was not treated for HLH. At 6 months, he was moderately cognitively impaired and participated with ADLs. The 2 patients who did not meet criteria for HLH had different outcomes. Patient 3 was severely cognitively impaired depending on a tracheostomy and gastrostomy as well as dependent for all ADLs. Patient 4 had mild cognitive impairment but was independent for all ADLs.
| DISCUSSION
FIRES is a catastrophic epileptic encephalopathy of uncertain etiology. The seizures are usually not responsive to antiepileptic medications, anesthetics, and/or typical immune modulating agents. Although innate immune activation is the hypothesized mechanism driving epileptogenesis in the acute period, 2,3,16 a specific etiology for this condition is still unknown. In our center, we observed a pattern of clinical deterioration in FIRES patients 3-4 weeks after presentation. Unexplained fever and multiorgan dysfunction prompted us to evaluate several patients for secondary HLH of which 3 met full criteria. The concurrence of these 2 rare disorders in these patients brought attention to several associations between the FIRES and HLH. In a comprehensive FIRES literature review, we found several patients with similar clinical deterioration and rash about 4 weeks after illness onset, 1, 11, 17, 18 but none mentioned HLH screening. Although the cooccurrence of systemic inflammatory response syndrome has been reported after status epilepticus, 19 to our knowledge, the coexistence of FIRES and HLH has not been described previously. We summarize our hypothesized mechanisms for the association between FIRES and secondary HLH observed in our cohort ( Figure 4) initiating with a nonspecific febrile illness triggering release of inflammatory molecules. In a genetically predisposed individual, anti-inflammatory mediators are unable to resolve inflammatory responses. 2, 20 Activated immune pathways in glial cells, neurons, F I G U R E 2 Cytokine/chemokine analysis respective to disease course and therapies received. IL-1β and IL-18 are depicted simultaneously.
Specific cytokine/chemokine values can be found in Table 2 . CTX, cyclophosphamide; IVIG/MP, intravenous immunoglobulin/ methylprednisolone; IV ketogenic diet; IVKD, HLH chemotherapy protocol 9 ; KD, ketogenic diet; PLEX, plasma exchange; RTX, rituximab FARIAS-MOELLER ET AL. astrocytes, and cellular components of the blood-brain barrier give rise to an uncontrolled neuroinflammatory cascade marked by production of inflammatory cytokines/chemokines and adhesion molecules that promote infiltration of peripheral immune effectors. 2 21 Models of SE show that recurrent seizure activity triggers neuroinflammation, thereby perpetuating a cycle of innate immune activation. 24 Put differently, sustained seizures, as those that occur in FIRES, lead to neuroinflammation, higher seizure burden, and further inflammation. Figure 4B demonstrates secondary HLH pathophysiology, which occurs when natural killer (NK) cells and T regulatory lymphocytes (Treg) are unable to regulate cytotoxic T lymphocyte (CTL) populations through a variety of genetic and acquired mechanisms. Hyperactivated CTLs secrete large amounts of interferon-γ (IFN-γ), thereby stimulating macrophages and inducing hemophagocytosis, culminating in an overwhelming cytokine storm. 8 Secondary HLH can occur via several mechanisms. 7 Through acquired defects in cytotoxicity, there is reduced NK cell function with decreased perforin expression, rendering these cells unable to regulate CTL. This phenomenon can be secondary to preexisting persistently elevated levels of cytokines, including IL-12, IL-18, and IL-6. However, in secondary HLH, there are alternative causes for hyperinflammation and abnormal cytotoxicity is rarely the disease driver. 8 Animal models have highlighted the role of innate immunity activation via excessive stimulation of Toll-like receptors, 7, 25 and HMGB1 has been implicated specifically in the development of macrophage-activating syndrome (MAS), which is classified among the secondary forms of HLH. 26 In our cohort, HMGB1 was elevated in every patient in CSF, but not in serum. IFN-γ, a central cytokine in HLH, 7 is also that has biochemical and physiologic functions in host defense, but also promotes oxidative stress, which may amplify cytotoxic effects. 27 Neopterin, which is a sensitive and specific marker for HLH 28 correlating with serum ferritin, 29 was markedly elevated in our FIRES cohort, consisting of the finding of increased IFN-γ production in these patients and similar to what is observed in HLH.
The mechanisms by which a systemic inflammatory response activates neuroinflammation are multifactorial, but disruption in the blood-brain barrier (BBB) that promotes "leakage" of peripheral cytokines and danger signals into the CNS may be of paramount importance. 20, 23, 30 Furthermore, altered BBB permeability may facilitate trafficking of innate and adaptive immune cells into the CNS, 20 triggering further activation of the brain-resident innate immune system, resulting in epileptogenesis and brain injury. A better understanding of systemic and intrathecal inflammatory changes in patients with FIRES will potentially allow us to identify the factors that may contribute to this self-perpetuating mechanism.
To better understand the processes that may underlie inflammatory epileptogenesis, we measured cytokine and chemokine levels in our patients with FIRES who were screened for HLH. Elevation of specific cytokines and chemokines in our cohort was highly variable, and there were discrepancies between levels measured in serum versus CSF. HMGB1, IL-6, CXCL8, CXCL9, and CXCL10 were found to be elevated in most patients, but the pattern of changes in these factors relative to the development of HLH were not consistent across subjects. IL-1 receptor type 1 (and IL-18) is the current focus of anakinra therapy and in models of FIRES. 18 Neither IL-1β nor IL-18 was elevated in CSF in our patients (Figure 3 ), which could explain the lack of response to anakinra. The overexpression of other chemokines and cytokines as well as HMGB1 may be relevant to inflammatory changes in this patient with calcium influx, changes in ion channels altering GABA and glutamate release/reuptake, modifications of GABA receptor trafficking, and deficient buffering of astrocytes with inability to reuptake potassium or glutamate. 21 33 and the decision to administer chemotherapy needs to be carefully weighed in critically ill patients with FIRES who meet criteria for HLH. We acknowledge several limitations of this small study. Not all patients were comprehensively screened. While one patient (Patient 4) did not have HLH, Patient 3 met 4/5 criteria necessary for diagnosis. It is possible that if comprehensive screening had been performed, he would have fully met criteria. Furthermore, the five children with FIRES (cared for previous to Patient 1) who were not screened for HLH had associated supporting clinical features outside HLH criteria such as multiorgan dysfunction (4/5), rash (3/5), ileus (4/5), and hemodynamic instability (4/5). It is possible that HLH incidence in our cohort is underestimated because patients were not screened. An additional limiting factor is the lack of specificity of secondary HLH criteria given that many of these features are frequently seen in critically ill patients with sepsis or systemic inflammatory response syndrome. 6, 11 Another limitation in the analysis of cytokine and chemokine levels in this study is the heterogeneity of samples relative to disease stage and the lack of matched serum samples for comparison in 3 patients. While every effort was made to process the samples quickly and under identical conditions, there are doubtless variations in sample stability that may impact detection of extremely sensitive factors such as IL-1β. 18 Likewise, the determination of control ranges for all of the factors is challenged by the unavailability of CSF from healthy control pediatric donors. From a mechanistic standpoint, it is currently unknown whether the changes we observed are a cause or an effect of the underlying seizures. How the levels of these factors relate to the multiple treatments administered and to ongoing seizure burden in each individual patient at the time of collection is also unclear.
| CONCLUSION
Febrile infection-related epilepsy syndrome is a rare disorder of unknown etiology and without clear diagnostic criteria. The co-occurrence of hemophagocytic lymphohistiocytosis in three patients with FIRES patients suggests the possibility of a common immune dysregulation phenotype, with inflammatory mediator cross talk between the CNS and the periphery serving as one mechanism underlying acute epileptogenesis in these patients. We note CSF neopterin to be markedly elevated in comparison with other CNS inflammatory conditions, and further studies are required to evaluate whether or not it can be used as an early biomarker. We recommend maintaining a high index of suspicion for secondary HLH in patients with FIRES, especially in the presence of other features associated with HLH, such as cholestasis, elevated transaminases and lactate dehydrogenase, rash, lymphadenopathy, and coagulopathy. 11 The decision to administer chemotherapy should always be made with detailed scrutiny of clinical and laboratory data, disease severity stratification, and close collaboration with expert consultants. We support collaborations via national and international databases to collectively gain more experience in understanding and managing these challenging patients.
